Zimmer Biomet (NYSE:ZBH – Get Free Report) and ICU Medical (NASDAQ:ICUI – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.
Profitability
This table compares Zimmer Biomet and ICU Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zimmer Biomet | 9.05% | 13.24% | 7.28% |
| ICU Medical | 2.15% | 7.50% | 3.91% |
Valuation and Earnings
This table compares Zimmer Biomet and ICU Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zimmer Biomet | $8.23 billion | 2.14 | $705.20 million | $3.85 | 23.68 |
| ICU Medical | $2.23 billion | 1.76 | $730,000.00 | $1.85 | 85.14 |
Zimmer Biomet has higher revenue and earnings than ICU Medical. Zimmer Biomet is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Zimmer Biomet and ICU Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zimmer Biomet | 3 | 13 | 7 | 1 | 2.25 |
| ICU Medical | 1 | 1 | 4 | 3 | 3.00 |
Zimmer Biomet presently has a consensus price target of $100.70, indicating a potential upside of 10.44%. ICU Medical has a consensus price target of $168.40, indicating a potential upside of 6.91%. Given Zimmer Biomet’s higher probable upside, equities analysts clearly believe Zimmer Biomet is more favorable than ICU Medical.
Institutional & Insider Ownership
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Comparatively, 2.1% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
Summary
Zimmer Biomet beats ICU Medical on 9 of the 15 factors compared between the two stocks.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
About ICU Medical
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
